Search
Now showing items 1-9 of 9
Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy.
(ELSEVIER SCI LTD, 2020-05-01)
BACKGROUND: Pre-clinical evidence suggests reduced efficacy of anticancer treatment in patients exposed to broad-spectrum antibiotics. It is hypothesised that this phenomenon may be explained by the effects of antibiotics ...
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
(BMJ PUBLISHING GROUP, 2020-01-01)
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple ...
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
(CELL PRESS, 2020-03-27)
Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
(TAYLOR & FRANCIS LTD, 2020-06-02)
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ...
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.
(NATURE PUBLISHING GROUP, 2020-02-07)
APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been implicated as a mediator of cancer evolution and therapeutic resistance. Mutational plasticity also drives generation of neoepitopes, which ...
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
(BMJ PUBLISHING GROUP, 2020-01-01)
BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%-60% ...
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
(NATURE PORTFOLIO, 2020-04-01)
The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic ...
RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
(WILEY, 2020-06-08)
Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune ...